arrow
B

Bernardo Stefanini

university of bologna
H指数:14
被引数:770

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Stratifying Cardiovascular Risk in Patients With HCC Receiving Atezolizumab/Bevacizumab: A Comparison of ESC and CARDIOSOR Scores

在采用阿替利珠单抗/贝伐珠单抗治疗的肝癌患者中分层心血管风险:ESC评分与CARDIOSOR评分的比较

2026-10-070
OAAI
A myeloid immunosuppressive phenotype defines primary refractoriness to atezolizumab Plus bevacizumab in hepatocellular caarcinoma.

髓系免疫抑制表型定义了肝细胞癌对阿替利珠单抗联合贝伐珠单抗的原发耐药性。

2026-06-150
OAAI
Reproducibility of segmentation and radiomic features in contrast-enhanced CT images of early, intermediate and advanced HCC patients: a multicenter study

早期、中期和晚期肝癌患者增强CT图像中分割和放射组学特征的可重复性:一项多中心研究

2026-04-260
PRE
Determinants of long-term survival from atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma

不可切除肝细胞癌患者接受阿替利珠单抗联合贝伐珠单抗长期生存的影响因素

2026-04-160
PRE
The use of advanced machine learning to predict outcomes after atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: a retrospective cohort study

使用高级机器学习方法预测阿替利珠单抗联合贝伐珠单抗治疗晚期肝细胞癌的结局:一项回顾性队列研究

2026-02-120
OAAI
Comparative Efficacy of Initial Treatment Strategies in Patients with Transarterial Chemoembolisation-Unsuitable Hepatocellular Carcinoma

经动脉化疗栓塞不适用肝癌患者的初始治疗策略比较疗效

2026-02-010
OA
Post-immunotherapy second-line strategies for hepatocellular carcinoma: State of the art and ongoing trials

Ascari, S.; Chen, R.; De Sinno, A.; Stefanini, B.; Cescon, M.; Serenari, M.; Mosconi, C.; Tovoli, F. 免疫治疗后的二线策略用于肝细胞癌:现状与正在进行的研究。世界胃肠病学杂志. 2026, 32, 111528. [Google Scholar] [CrossRef] [PubMed]

2026-01-212
PRE
Tumour Burden Score as a Predictor of Extrahepatic Progression After Transarterial Chemoembolization for Hepatocellular Carcinoma: An Observational Multicenter Study

肿瘤负荷评分作为肝细胞癌经动脉化疗栓塞术后肝外进展的预测因子:一项多中心观察性研究

2026-01-140
PRE
Tumour Burden Score as a Predictor of Extrahepatic Progression After Transarterial Chemoembolization for Hepatocellular Carcinoma: An Observational Multicenter Study

肿瘤负荷评分作为肝细胞癌经动脉化疗栓塞术后肝外进展的预测指标:一项观察性多中心研究

2026-01-140
PRE
Tumour Burden Score as a Predictor of Extrahepatic Progression After Transarterial Chemoembolization for Hepatocellular Carcinoma: An Observational Multicenter Study

肿瘤负荷评分作为肝细胞癌经动脉化疗栓塞术后肝外进展的预测因子:一项多中心观察性研究

2026-01-140
PRE
Tumour Burden Score as a Predictor of Extrahepatic Progression After Transarterial Chemoembolization for Hepatocellular Carcinoma: An Observational Multicenter Study

肿瘤负荷评分作为肝细胞癌经动脉化疗栓塞术后肝外进展的预测指标:一项观察性多中心研究

2026-01-140
PRE
Tumour Burden Score as a Predictor of Extrahepatic Progression After Transarterial Chemoembolization for Hepatocellular Carcinoma: An Observational Multicenter Study

肿瘤负荷评分作为肝细胞癌经动脉化疗栓塞术后肝外进展的预测指标:一项观察性多中心研究

2026-01-140
PRE
Tumour Burden Score as a Predictor of Extrahepatic Progression After Transarterial Chemoembolization for Hepatocellular Carcinoma: An Observational Multicenter Study

肿瘤负荷评分作为肝细胞癌经动脉化疗栓塞术后肝外进展的预测指标:一项多中心观察性研究

2026-01-140
PRE
The Effect of Metformin on Atezolizumab/Bevacizumab Treatment in Patients with Carcinoma and Diabetes

二甲双胍对接受阿替利珠单抗/贝伐珠单抗治疗的癌病患者的影响

2026-01-010
PRE
Lenvatinib versus sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: the LEVIATHAN Study

伦伐替尼对比索拉非尼作为阿替利珠单抗联合贝伐珠单抗后肝癌的二线治疗:LEVIATHAN 研究

2025-09-230
OAAI
Hepatitis C Eradication Improves Oncologic and Clinical Outcomes in Patients Treated With Atezolizumab Plus Bevacizumab

丙型肝炎清除可改善接受阿替利珠单抗联合贝伐珠单抗治疗患者的肿瘤学和临床结局

2025-09-220
PREAI